MNBTD
RARE icon

Moody National Bank Trust Division’s Ultragenyx Pharmaceutical RARE Stock Holding History

Moody National Bank Trust Division’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-85
Closed -$6K – 828
2019
Q1 		$6K Sell
85
-46
-35% -$2.63K ﹤0.01% 799
2018
Q4 		$6K Buy
+131
New +$7.16K ﹤0.01% 706

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Moody National Bank Trust Division's RARE Position: Q2 2019 in Review

Moody National Bank Trust Division sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2019, closing a stake of 85 shares — an estimated $6K sold.

Moody National Bank Trust Division first reported a position in RARE in Q4 2018 and held it in 2 quarters. The position peaked at $6K in Q1 2019. 170 funds tracked by Wall St. Rank hold RARE as of Q2 2019.

  • Moody National Bank Trust Division reported no remaining Ultragenyx Pharmaceutical position as of Q2 2019 after selling out during the quarter.
  • Moody National Bank Trust Division sold 85 Ultragenyx Pharmaceutical shares in Q2 2019, an estimated $6K.
  • Moody National Bank Trust Division first reported a position in Ultragenyx Pharmaceutical in Q4 2018 and held it in 2 quarters.
  • Moody National Bank Trust Division's Ultragenyx Pharmaceutical position peaked at $6K in Q1 2019.
  • 170 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2019.

Based on Moody National Bank Trust Division's 13F filing for Q2 2019, filed 22 Jul 2019.